000302017 001__ 302017
000302017 005__ 20250614115244.0
000302017 0247_ $$2doi$$a10.14740/gr2036
000302017 0247_ $$2pmid$$apmid:40503193
000302017 0247_ $$2pmc$$apmc:PMC12151123
000302017 0247_ $$2ISSN$$a1918-2805
000302017 0247_ $$2ISSN$$a1918-2813
000302017 037__ $$aDKFZ-2025-01215
000302017 041__ $$aEnglish
000302017 082__ $$a610
000302017 1001_ $$aCorral, Juan E$$b0
000302017 245__ $$aHigh Seroprevalence of Helicobacter pylori and CagA/VacA Virulence Factors in Northern Central America.
000302017 260__ $$aQuebec, Canada J5R 5Z3$$b[Verlag nicht ermittelbar]$$c2025
000302017 3367_ $$2DRIVER$$aarticle
000302017 3367_ $$2DataCite$$aOutput Types/Journal article
000302017 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1749820941_3950
000302017 3367_ $$2BibTeX$$aARTICLE
000302017 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302017 3367_ $$00$$2EndNote$$aJournal Article
000302017 520__ $$aNorthern Central America is unique in the Western Hemisphere, with a high incidence of gastric cancer, low/middle-income country (LMIC) status, and a substantial emigration to the United States. The two primary Helicobacter pylori (H. pylori) virulence factors related to carcinogenesis are cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA). The prevalence of these factors may help delineate gastric cancer risk in the region. We aimed to characterize the H. pylori seroprevalence and virulence factors in two Central American Countries (Honduras and Guatemala).Healthy volunteers from Western Honduras and Central-Western Guatemala were recruited and tested for antibodies against 13 H. pylori antigens using a novel multiplex serology assay. H. pylori seropositivity was defined as positivity for ≥ 4 antigens, and active infection was defined as positivity for a combination of 2/4 antigens: VacA, GroEl, HcpC, and HP1564, based upon the literature. Multivariate logistic regression models were used to estimate the odds ratios for the association between H. pylori and CagA positivity.A total of 1,143 healthy adults were tested using the H. pylori multiplex serology assay (444 in Guatemala and 699 in Honduras). Mean age was 54.2 ± 14.5 years, 46.2% were male, 60% were from rural settings, and 56% lived > 1,000 meters above sea level. H. pylori prevalence was 87%, and 83% with active infection. The CagA and VacA seropositivity rates were 82% and 75%, respectively. No significant differences were noted according to country, age group, sex, or rural/urban location. None of the socioeconomic variables were significantly associated with the presence of H. pylori or CagA.A high prevalence of H. pylori, CagA, and VacA is observed in Honduras and Guatemala, with implications for Northern Central America and immigrants from the region. Innovative and resource-appropriate primary and secondary prevention programs are needed.
000302017 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000302017 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302017 650_7 $$2Other$$aCagA
000302017 650_7 $$2Other$$aCentral America
000302017 650_7 $$2Other$$aGastric cancer
000302017 650_7 $$2Other$$aHelicobacter pylori
000302017 650_7 $$2Other$$aVacA
000302017 7001_ $$aNorwood, Dalton A$$b1
000302017 7001_ $$aAlvarez, Christian S$$b2
000302017 7001_ $$aKim, Do Han$$b3
000302017 7001_ $$aMontalvan-Sanchez, Eleazar E$$b4
000302017 7001_ $$aRivera-Andrade, Alvaro$$b5
000302017 7001_ $$aRamirez-Zea, Manuel$$b6
000302017 7001_ $$aMcGlynn, Katherine A$$b7
000302017 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b8$$udkfz
000302017 7001_ $$aDominguez, Ricardo L$$b9
000302017 7001_ $$aMorgan, Douglas R$$b10
000302017 773__ $$0PERI:(DE-600)2475913-2$$a10.14740/gr2036$$gVol. 18, no. 3, p. 119 - 128$$n3$$p119 - 128$$tGastroenterology research$$v18$$x1918-2805$$y2025
000302017 909CO $$ooai:inrepo02.dkfz.de:302017$$pVDB
000302017 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000302017 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000302017 9141_ $$y2025
000302017 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGASTROENTEROL RES : 2022$$d2024-12-13
000302017 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000302017 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000302017 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000302017 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-13
000302017 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000302017 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-13
000302017 9201_ $$0I:(DE-He78)D320-20160331$$kD320$$lInfektionen und Krebs-Epidemiologie$$x0
000302017 980__ $$ajournal
000302017 980__ $$aVDB
000302017 980__ $$aI:(DE-He78)D320-20160331
000302017 980__ $$aUNRESTRICTED